Irofulven induces replication-dependent CHK2 activation related to p53 status

Biochemical Pharmacology

Volumn 73, Issue 4, 2007, Pages 469-480

  Wang, Yutian ^a   Wiltshire, Timothy ^a   Senft, Jamie ^a   Reed, Eddie ^a   Wang, Weixin ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; Chemosensitivity; CHK2; Irofulven; p53; Replication

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; APHIDICOLIN; CHECKPOINT KINASE 2; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; DNA REPLICATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; G1 PHASE; G2 PHASE; HCT116 CELLS; HISTONES; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; S PHASE; SESQUITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845941651     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.023     Document Type: Article

References (59)

1. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60 14 (2000) 3689-3695
2. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 6811 (2000) 433-439
3. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15 17 (2001) 2177-2196
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3 3 (2003) 155-168
5. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 3 (1997) 323-331
6. Bartek J., and Lukas J. CHK1 and CHK2 kinases in checkpoint control and cancer. Cancer Cell 3 5 (2003) 421-429
7. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2 9 (2002) 647-656
8. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2 8 (2002) 594-604
9. Boddy M.N., Shanahan P., McDonald W.H., Lopez-Girona A., Noguchi E., Yates I.J., et al. Replication checkpoint kinase Cds1 regulates recombinational repair protein Rad60. Mol Cell Biol 23 16 (2003) 5939-5946
10. Zhang J., Willers H., Feng Z., Ghosh J.C., Kim S., Weaver D.T., et al. CHK2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24 2 (2004) 708-718
11. Lee J.S., Collins K.M., Brown A.L., Lee C.H., and Chung J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404 6774 (2000) 201-204
12. Wang H.C., Chou W.C., Shieh S.Y., and Shen C.Y. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining. Cancer Res 66 3 (2006) 1391-1400
13. Zhuang J., Zhang J., Willers H., Wang H., Chung J.H., van Gent D.C., et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res 66 3 (2006) 1401-1408
14. Castedo M., Perfettini J.L., Roumier T., Yakushijin K., Horne D., Medema R., et al. The cell cycle checkpoint kinase CHK2 is a negative regulator of mitotic catastrophe. Oncogene 23 25 (2004) 4353-4361
15. Castedo M., Perfettini J.L., Roumier T., Valent A., Raslova H., Yakushijin K., et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23 25 (2004) 4362-4370
16. Yang S., Kuo C., Bisi J.E., and Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4 11 (2002) 865-870
17. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21 19 (2002) 5195-5205
18. Hirao A., Cheung A., Duncan G., Girard P.M., Elia A.J., Wakeham A., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22 18 (2002) 6521-6532
19. Jack M.T., Woo R.A., Hirao A., Cheung A., Mak T.W., and Lee P.W. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 99 15 (2002) 9825-9829
20. Keramaris E., Hirao A., Slack R.S., Mak T.W., and Park D.S. ATM can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J Biol Chem (2003)
21. Brodsky M.H., Weinert B.T., Tsang G., Rong Y.S., McGinnis N.M., Golic K.G., et al. Drosophila melanogaster MNK/Chk2 and p53 regulate multiple DNA repair and apoptotic pathways following DNA damage. Mol Cell Biol 24 3 (2004) 1219-1231
22. Xu J., Xin S., and Du W. Drosophila Chk2 is required for DNA damage-mediated cell cycle arrest and apoptosis. FEBS Lett 508 3 (2001) 394-398
23. Peters M., DeLuca C., Hirao A., Stambolic V., Potter J., Zhou L., et al. Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proc Natl Acad Sci USA 99 17 (2002) 11305-11310
24. Stevens C., Smith L., and La Thangue N.B. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5 5 (2003) 401-409
25. Stiewe T., and Putzer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26 4 (2000) 464-469
26. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F., et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3 6 (2001) 552-558
27. Chehab N.H., Malikzay A., Appel M., and Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14 3 (2000) 278-288
28. Shieh S.Y., Ahn J., Tamai K., Taya Y., and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14 3 (2000) 289-300
29. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287 5459 (2000) 1824-1827
30. Tominaga K., Morisaki H., Kaneko Y., Fujimoto A., Tanaka T., Ohtsubo M., et al. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 274 44 (1999) 31463-31467
31. Shigeishi H., Yokozaki H., Oue N., Kuniyasu H., Kondo T., Ishikawa T., et al. Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations. Int J Cancer 99 1 (2002) 58-62
32. Matsui T., Katsuno Y., Inoue T., Fujita F., Joh T., Niida H., et al. Negative regulation of Chk2 expression by p53 is dependent on the CCAAT-binding transcription factor NF-Y. J Biol Chem 279 24 (2004) 25093-25100
33. MacDonald J.R., Muscoplat C.C., Dexter D.L., Mangold G.L., Chen S.F., Kelner M.J., et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57 2 (1997) 279-283
34. Sato Y., Kashimoto S., MacDonald J.R., and Nakano K. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur J Cancer 37 11 (2001) 1419-1428
35. Friedman H.S., Keir S.T., Houghton P.J., Lawless A.A., Bigner D.D., and Waters S.J. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol 48 5 (2001) 413-416
36. Hidalgo M., Izbicka E., Eckhardt S.G., MacDonald J.R., Cerna C., Gomez L., et al. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anticancer Drugs 10 9 (1999) 837-844
37. Britten C.D., Hilsenbeck S.G., Eckhardt S.G., Marty J., Mangold G., MacDonald J.R., et al. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59 5 (1999) 1049-1053
38. Murgo A., Cannon D.J., Blatner G., and Cheson B.D. Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Huntingt) 13 2 (1999) p. 233, 237, 238
39. Kelner M.J., McMorris T.C., Rojas R.J., Trani N.A., Velasco T.R., Estes L.A., et al. Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs 20 3 (2002) 271-279
40. Senzer N., Arsenau J., Richards D., Berman B., MacDonald J.R., and Smith S. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol 28 1 (2005) 36-42
41. Woo M.H., Peterson J.K., Billups C., Liang H., Bjornsti M.A., and Houghton P.J. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models. Cancer Chemother Pharmacol 55 5 (2005) 411-419
42. Wang J., Wiltshire T., Wang Y., Mikell C., Burks J., Cunningham C., et al. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem 279 38 (2004) 39584-39592
43. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 5393 (1998) 1497-1501
44. Jallepalli P.V., Lengauer C., Vogelstein B., and Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem (2003)
45. Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., and Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60 8 (2000) 2108-2112
46. Wang W., Waters S.J., MacDonald J.R., Roth C., Shentu S., Freeman J., et al. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res 22 2A (2002) 559-564
47. Xu B., Kim S., and Kastan M.B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21 10 (2001) 3445-3450
48. Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., and Elledge S.J. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97 19 (2000) 10389-10394
49. Melchionna R., Chen X.B., Blasina A., and McGowan C.H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nat Cell Biol 2 10 (2000) 762-765
50. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60 21 (2000) 5934-5936
51. Lee C.H., and Chung J.H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem 276 32 (2001) 30537-30541
52. Xu X., Tsvetkov L.M., and Stern D.F. Chk2 activation and phosphorylation-dependent oligomerization. Mol Cell Biol 22 12 (2002) 4419-4432
53. Ward I.M., Wu X., and Chen J. Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks. J Biol Chem 276 51 (2001) 47755-47758
54. Huberman J.A. New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha. Cell 23 3 (1981) 647-648
55. Izbicka E., Davidson K., Lawrence R., Cote R., MacDonald J.R., and Von Hoff D.D. Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res 19 2A (1999) 1299-1307
56. Poindessous V., Koeppel F., Raymond E., Comisso M., Waters S.J., and Larsen A.K. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 9 7 (2003) 2817-2825
57. Serova M., Calvo F., Lokiec F., Koeppel F., Poindessous V., Larsen A.K., et al. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol 57 4 (2006) 491-499
58. Ismail I.H., Nystrom S., Nygren J., and Hammarsten O. Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks. J Biol Chem 280 6 (2005) 4649-4655
59. Buscemi G., Perego P., Carenini N., Nakanishi M., Chessa L., Chen J., et al. Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 23 46 (2004) 7691-7700